These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 11195289)

  • 21. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.
    Jassem J; Carroll C; Ward SE; Simpson E; Hind D
    Eur J Cancer; 2009 Nov; 45(16):2749-58. PubMed ID: 19615886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
    Barnett CM
    Pharmacotherapy; 2009 Dec; 29(12):1482-90. PubMed ID: 19947807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
    Fossati R; Confalonieri C; Torri V; Ghislandi E; Penna A; Pistotti V; Tinazzi A; Liberati A
    J Clin Oncol; 1998 Oct; 16(10):3439-60. PubMed ID: 9779724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of docetaxel into adjuvant breast cancer treatment regimens.
    Hortobagyi GN
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):27-33. PubMed ID: 12108895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
    Mauri D; Polyzos NP; Salanti G; Pavlidis N; Ioannidis JP
    J Natl Cancer Inst; 2008 Dec; 100(24):1780-91. PubMed ID: 19066278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to maximize the efficacy of taxanes in breast cancer.
    Tubiana-Hulin M
    Cancer Treat Rev; 2005; 31 Suppl 4():S3-9. PubMed ID: 16360546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic treatment of metastatic breast cancer.
    Johnston SR
    Hosp Med; 2001 May; 62(5):289-95. PubMed ID: 11385890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of taxanes in the treatment of breast cancer.
    Nabholtz JM; Gligorov J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1073-94. PubMed ID: 15957963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
    Nabholtz JM; Tonkin K; Smylie M; Au HJ; Lindsay MA; Mackey J
    Expert Opin Pharmacother; 2000 Jan; 1(2):187-206. PubMed ID: 11249542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
    Pentheroudakis G; Razis E; Athanassiadis A; Pavlidis N; Fountzilas G
    Med Oncol; 2006; 23(2):147-60. PubMed ID: 16720915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.